Madrigal Pharmaceuticals Inc.
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Mar 2022 | — | $145.7M | $42.3M |
| Jun 2022 | $48.7M | $83.5M | $53.3M |
| Sep 2022 | $49.0M | $10.7M | $59.3M |
| Dec 2022 | $49.3M | $197.4M | $331.5M |
| Mar 2023 | $84.0M | $150.1M | $113.3M |
| Jun 2023 | $99.2M | $103.5M | $77.2M |
| Sep 2023 | $114.7M | $22.2M | $62.1M |
| Dec 2023 | $115.5M | $405.3M | $99.9M |
| Mar 2024 | $116.1M | $850.8M | $622.5M |
| Jun 2024 | $116.6M | $857.1M | $494.6M |
| Sep 2024 | $117.1M | $777.2M | $232.7M |
| Dec 2024 | $117.6M | $754.4M | $100.0M |
| Mar 2025 | $118.0M | $710.6M | $183.6M |
| Jun 2025 | $118.4M | $696.0M | $186.2M |
| Sep 2025 | $339.8M | $625.7M | $295.7M |
| Dec 2025 | $339.9M | $602.7M | $198.7M |
| Mar 2026 | $340.3M | $543.5M | $227.0M |
| Jun 2026 | $340.8M | $523.7M | $292.7M |